Aveo Pharmaceuticals (AVEO) 2.04 $AVEO New finance chief

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 7:06 PM

Aveo Pharmaceuticals (AVEO) 2.04 $AVEO

New finance chief at Aveo Oncology
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 7:43AM CDT

AVEO: 2.04 (+0.12)

AVEO Names Keith S. Ehrlich as Chief Financial Officer
Business Wire - Wed Apr 22, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Keith S. Ehrlich to the position of chief financial officer. In this role, Mr. Ehrlich will be responsible for the company's financial and administrative strategy and management, and will serve on the executive leadership team which governs corporate strategy. He will report to Michael Bailey, AVEO's president and chief executive officer.
AVEO: 2.04 (+0.12)

The Medicines Co.'s New Minocin Formulation Approved - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:21PM CDT
The Medicines Company (MDCO) received approval from the FDA for a new formulation of Minocin.
MDCO: 27.84 (+0.25), HZNP: 30.96 (+0.10), AVEO: 2.04 (+0.12), OSIR: 16.35 (-0.10)

Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 5:05PM CDT
Bristol-Myers (BMY) announced encouraging results from a phase II study Opdivo in combination with Yervoy.
BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)

Actavis' Botox Upper Limb Spasticity Label Expanded by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 3:08PM CDT
Actavis' (ACT) Botox has been granted further FDA approval; adds upper limb spasticity to its label.
CRMD: 8.86 (-0.28), BIIB: 423.57 (+1.46), ACT: 295.22 (+0.69), AVEO: 2.04 (+0.12)

AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 8:43AM CDT
AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue?
AVEO: 2.04 (+0.12)

Merck's Keytruda Tops Melanoma, Lung Cancer Studies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 5:26PM CDT
Merck (MRK) presented encouraging results at the annual meeting of the American Association for Cancer Research from studies evaluating its anti-PD-1 therapy, Keytruda.
MRK: 57.69 (+0.03), HZNP: 30.96 (+0.10), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)

Athersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 5:14PM CDT
Athersys (ATHX) announced disappointing interim results from a phase II study on MultiStem cell therapy.
BIIB: 423.57 (+1.46), AZN: 73.35 (+0.65), AVEO: 2.04 (+0.12), ATHX: 1.34 (+0.01)

Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 4:58PM CDT
Bristol-Myers' Study on Opdivo was Halted early as it meets key endpoints.
BIIB: 423.57 (+1.46), MRK: 57.69 (+0.03), AVEO: 2.04 (+0.12), BMY: 66.60 (-0.21)

Oncolytics' Reolysin Gets One More Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 2:20PM CDT
Oncolytics' (ONCY) lead candidate Reolysin has been granted orphan drug status by the FDA for the treatment of malignant gliomas.
ONCY: 0.80 (unch), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AMGN: 169.10 (+0.64)

TrovaGene's (TROV) PCM Data Impresses, Shares Rally - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 2:08PM CDT
Shares of TrovaGene Inc. (TROV) surged 20.14% to close at $8.53 on Apr 17, after the company reported favorable clinical data for its Precision Cancer Monitoring (PCM) technology.
TROV: 8.58 (-0.27), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AMGN: 169.10 (+0.64)

Zacks Rank #1 Additions for Monday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
ACHC: 71.98 (-0.47), ANET: 66.27 (+0.40), ABG: 86.97 (-0.16), AVEO: 2.04 (+0.12), ADUS: 27.60 (-0.33)

AVEO Oncology Announces Presentation of AV-380 Preclinical Data in Cancer Associated Cachexia at 2015 Annual Meeting of the American Association of Cancer Research
Business Wire - Mon Apr 20, 6:00AM CDT
AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a preclinical study of AV-380, the Company's potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in a cachectic human tumor xenograft model with significantly increased plasma GDF15 levels. The data were presented in a poster titled "Effective treatment of cancer associated cachexia by AV-380, a GDF15 inhibitory antibody" at the 2015 Annual Meeting of the American Association of Cancer Research in Philadelphia from April 18-22.
AVEO: 2.04 (+0.12)

Receptos Gains on Positive Phase II Data on Ozanimod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:28PM CDT
Receptos (RCPT) announced positive results from the maintenance period of the TOUCHSTONE study on ozanimod for ulcerative colitis.
ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), RCPT: 166.76 (-3.37), AFFX: 12.57 (-0.13)

AVEO Pharmaceuticals (AVEO) Jumps: Stock Moves Up 16.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 7:51AM CDT
AVEO Pharmaceuticals, Inc. (AVEO) was a big mover last session, as its shares rose over 16% on the day.
AVEO: 2.04 (+0.12), AFFX: 12.57 (-0.13)

AstraZeneca's Onglyza Label Needs Revision per FDA Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 5:04PM CDT
AstraZeneca's (AZN) Onglyza and Kombiglyze XR labels have been recommended to include new safety information as per an FDA panel.
MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AVEO: 2.04 (+0.12), LLY: 72.30 (+0.09)

The Medicines Co.'s Kengreal Backed for FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:57PM CDT
The Medicines Company's (MDCO) Kengreal is a step closer to U.S. approval with the FDA panel giving a favorable opinion for the treatment of percutaneous coronary intervention.
MDCO: 27.84 (+0.25), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), AVEO: 2.04 (+0.12)

Glaxo Downgraded to Strong Sell, Delete from Your Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:05PM CDT
On Apr 15, Zacks Investment Research downgraded GlaxoSmithKline plc (GSK) to a Zacks Rank #5 (Strong Sell); delete from your portfolio.
ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), GSK: 46.57 (-0.67), AFFX: 12.57 (-0.13)

GW Pharmaceuticals Up to Strong Buy on Strong Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 3:27PM CDT
On Apr 16, Zacks Investment Research upgraded GW Pharmaceuticals plc (GWPH) to a Zacks Rank #1 (Strong Buy); is it in your portfolio?
GWPH: 113.04 (-0.05), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AFFX: 12.57 (-0.13)

Two Sub $2 Biotech Stocks On The Move
Bret Jensen - at Seeking Alpha - Thu Apr 16, 2:29PM CDT

ZGNX: 1.63 (-0.02), AVEO: 2.04 (+0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dentsply Sirona Faces Insider Troubles: An Investor Call

Are Dentsply Sirona Insiders on Thin Ice? The stock market's a tumultuous sea, and right now, it seems like some of those at the helm of Dentsply Sirona Inc. might be rocking the boat a bit too much. Let me tell you, navigating these corporate storms isn't for the faint-hearted. The latest noise coming from Halper Sadeh LLC suggests that some directors and officers over...

CME Group Smashes FX Open Interest Record Again

Shattering Records: CME Group's Latest Milestone Well, here's a juicy nugget for your investment playbook. On September 4, 2026, CME Group proved, once again, why they're the big dog in the derivatives yard, announcing a new record in FX open interest—4,410,167 contracts! This tops the previous mark of 4,269,622 contracts set just a few months back. The futures and...

AB SKF to Hold EGM, Spin Off Automotive Assets

SKF's Extraordinary Meeting: A Pivotal Moment AB SKF, a heavyweight in the industrial technology sector, is summoning its shareholders for an Extraordinary General Meeting on October 1, 2026. The venue? The Elite Park Avenue Hotel in Gothenburg, Sweden—sounds fancy, but don't expect to hear a string quartet at this shindig. What's truly on the agenda is a critical...

Universal Music Wraps €250M Share Buyback Plan

Universal's Encore Performance in the Markets Universal Music Group (EURONEXT: UMG), the behemoth in music-based entertainment, just wrapped up its €250 million share buyback program. Talk about a grand finale! In a week’s worth of maneuvering from August 31 to September 4, they snagged 294,340 of their own shares, all for the pretty price of €14.65 a pop. Grand...

Early Orders Key for Custom Kids' Gifts This Season

Unwrap the Secret to Perfect Holiday Presents When it comes to giving the little ones something special for the holidays, the trick lies in timing. Not your run-of-the-mill timing, mind you—I'm talking about understanding how handcrafted, personalized toys can make or break the season. If you've ever scrambled for a last-minute gift, you know how that shaky feeling sets...

AXIS-Y: Global Expansion Fueled by KRW 430B Valuation

Rewriting the Playbook in Global Skincare AXIS-Y decided to do things their way, not just because they could afford to, but because they believed in their vision. Their strategy defies the trends-driven tactics of this cutthroat beauty world. Instead, they’ve been all about climate-inspired products and vegan, cruelty-free standards. And now, after notching up some...

Sony Expands Versatile Wireless Headphone Lineup: 2026

Renewed Focus on Sound: Sony's Latest Headphones Sony's dipping into the headphone market this time with a splash of style and sound signature updates. We've got the WH-1000XM4C, a next-gen version of the top-dog noise-cancelling cans, that are gonna catch the eye of every audiophile and traveler out there. WH-1000XM4C: The Flagship gets a Lift What they're offering is...

West Texas Weather Shapes Home Design Decisions

West Texas Weather: A Tough Customer for Home Builders You'd think building a house is a straightforward gig, but slap it down in West Texas, and we're talking a whole different ballgame. With its brutal heat, howling winds, and wild temperature swings, Odessa isn't just painting by numbers. It's where Mother Nature is your uninvited consultant on every single...

Thermoplastic Polyimide: A $0.86 Billion Market by 2032

It's not often you get hyped about a compound with a name like 'thermoplastic polyimide,' but hold your horses—this isn't just any chemical. If you're watching markets with a sharp eye, you’ll see this thing estimated at $0.56 billion in 2026, gunning for a hefty $0.86 billion by 2032. We're talking about a solid 7.4% CAGR ride here folks, according to new data from...

Interventional Ophthalmology: Early Eye Care Strategies Evolve

Proactive Eye Care: The New Frontier Today's eye care landscape is all about catching things early, folks. Long gone are the days of waiting for eyesight to deteriorate before rushing to the nearest eye doc. In Racine, interventional ophthalmology is shifting gears towards preventive care—looking ahead to stop eye diseases in their tracks before they muck up a person's...